Saad Mark E
SEC Form 4 insider trading activity
Saad Mark E has filed 3 SEC Form 4 filings (7 transaction rows) across 1 company, with disclosures dating back to 2025. 2 of those filings fall inside the rolling window. Most recent filing: Jun 11, 2026.
On the most recent filing, Saad Mark E is listed as Director at Axsome Therapeutics, Inc. Inside the rolling window, Saad Mark E reported no open-market purchases and 1 open-market sale totaling $6.2M in AXSM.
Companies traded
Other insiders at AXSM
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$6.2M
reported sales (SEC code S)
Companies
1
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
| Date | Ticker | Type | Value |
|---|---|---|---|
| Sep 5, 2025 | AXSM | Sale | $1.1M |
Frequently asked questions
How many SEC Form 4 filings has Saad Mark E made?
Saad Mark E has filed 3 SEC Form 4 filings (7 transaction rows) across 1 company since 2025.
Which companies does Saad Mark E trade?
Saad Mark E has filed SEC Form 4 disclosures for 1 company, including AXSM.
When was Saad Mark E's most recent SEC Form 4 filing?
Saad Mark E's most recent SEC Form 4 filing on Tracefour is dated Jun 11, 2026.
What is Saad Mark E's total buy and sell value in the current window?
Inside the rolling retention window, Saad Mark E bought $0 and sold $6.2M based on SEC Form 4 filings.
What was Saad Mark E's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 37,577 AXSM shares on 2025-12-31, worth $6.2M, per SEC Form 4 filings.